Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-06-20
2006-06-20
Andres, Janet L. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S139100, C424S141100, C424S142100
Reexamination Certificate
active
07063843
ABSTRACT:
Human protein C and activated protein C were shown to bind to endothelium specifically, selectively and saturably (Kd=30 nM, 7000 sites per cell) in a Ca2+dependent fashion. Expression cloning revealed a 1.3 kb cDNA that coded for a novel type I transmembrane glycoprotein capable of binding protein C. This protein appears to be a member of the CD1/MHC superfamily. Like thrombomodulin, the receptor involved in protein C activation, the endothelial cell protein C receptor (EPCR) function and message are both down regulated by exposure of endothelium to TNF. Identification of EPCR as a member of the CD1/MHC superfamily provides insights into the role of protein C in regulating the inflammatory response, and determination of methods for pharmaceutical use in manipulating the inflammatory response.
REFERENCES:
patent: 3625214 (1971-12-01), Higuchi
patent: 4244946 (1981-01-01), Rivier
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guilleman et al.
patent: 4629784 (1986-12-01), Stammer
patent: 4782137 (1988-11-01), Hopp et al.
patent: 4789734 (1988-12-01), Pierschbacher
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5009889 (1991-04-01), Taylor et al.
patent: 5147638 (1992-09-01), Esmon et al.
patent: 5298599 (1994-03-01), Rezaie et al.
patent: 5695993 (1997-12-01), Fukudome et al.
patent: 5698189 (1997-12-01), Rowe et al.
patent: 5749968 (1998-05-01), Melanson et al.
patent: 5779673 (1998-07-01), Roth et al.
patent: 5804392 (1998-09-01), Esmon et al.
patent: WO 96/05303 (1996-02-01), None
patent: WO 96/20732 (1996-07-01), None
patent: WO 96/21470 (1996-07-01), None
patent: WO 98/20041 (1998-05-01), None
Abe, et al., “Granulocyte proteases and hydrogen peroxide synergistically inactive thrombomodulin of endothelial cells in vitro,”J. Lab. Clin. Med. 123(6):874-881 (1994).
ACCP/SCCM Consensus Conference, “Definitions for Spesis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis,”Chest101(6):1644-1655 (1992).
Agrawal, et al., “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus,”Proc. Natl. Acad. Sci. USA85(19):7079-7083 (1988).
Arend, et al., “Building of IL-1α, IL-1β, and IL-1 Receptor Antagonist by Soluble IL-1 Receptors and Levels of Soluble IL-1 Receptors in Synovial Fluids,”J. Immunol. 153:4766-4774 (1994).
Asakura, et al., “Plasma Levels of Soluble Thrombomodulin Increase in Cases of Disseminated Intravascular Coagulation With Organ Failure,”Am. J. Hematol. 38:281-287 (1991).
Askew, B., et al., “Molecular Recognition with Convergent Functional Groups, 6, Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components”,J. Am. Chem. Soc., 111:1082-1090 (1989).
Bangalore, et al., “High affinity binding sites for activated protein C and protein C on cultured human umbilical vein endothelial cells. Independent of protein S and distinct from known ligands,”Thromb Haemos72(3):465-74 (1994).
Berg, et al., “Aberrant RNA splicing of the protein C and protein S genes in health individuals,”Blood Coag Fibrinol. 7:625-631 (1996).
Blume, et al., “Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter,”Nucleic Acids Res. 20(7):1777-84 (1992).
Bock, “Active Site Selective Labeling of Serine Proteases with Spectroscopic Probes Using Thioester Peptide Chloromethyl Ketones: Demonstration of Thrombin Labeling UsingNx-[(Acetylthio)acetyl]-D-Phe-Pro-Arg-CH2C1,”Biochemistry27:6633-6639 (1988).
Boehme, et al., “Release of thrombomodulin from endothelial cells by concentrated action of TNF-α and neutrophils:in vivoandin vitrostudies,”Immunology87:134-140 (1996).
Bourin & Lindahl, “Review Article: Glycosaminoglycans and the regulation of blood coagulation,”Biochem. J. 289:313-330 (1993).
Clackson, et al., “Making antibody fragments using phage display libraries,”Nature352:624-688 (1991).
Conway & Resenberg, “Tumor Necrosis Factor Suppresses Transcription of the Thrombomodulin Gene in Endothelial Cells,”Mol. Cell. Biol. 8(12):5588-5592 (1988).
Cooney, et al., “Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro,”Science. 241(4864):456-9 (1988).
Crooke, et al., “Progress toward oligonucleotide therapeutics: pharmacodynamic properties,”FASEB J. 7(6):533-9 (1993).
Curtis, et al., “IL-1 and its receptor are translocated to the nucleus,”J. Immunol. 144:1295-1303 (1990).
Dahlbäck, “Inhibition of Protein CaCofactor Function of Human and Bovine Protein S by C4b-binding Protein,”J. Biol. Chem. 261(26):12022-12027 (1986).
Dahlbäck, “Protein S and C4b-Binding Protein: Components Involved in the Regulation of the Protein C Anticoagulant System,”Thromb. Haemostas. 66:49-61 (1991).
Daugherty, et al., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD 18 component of leukocyte integrins,”Nucl. Acids Res. 19(9):2471-2476.
Dittman & Majerus, “Structure and Function of Thrombomodulin: A Natural Anticoagulant,”Blood75(2):329-336 (1990).
Dittman, “Thrombomodulin—Biology and Potential Cadiovascular Applications,”Trends Cardiovasc. Med. 1(8):331-336 (1991).
Dreyfus, et al., “Treatment of Homozygous Protein C Deficiency and Neonatal Purpura Fulminans with a Purified Protein C Concentrate,”N. Engl. J. Med. 325(22):1565-1568 (1991).
Duval-Valentin, et al., “Specific inhibition of transcription by triple helix-forming oligonucleotides,”Proc Natl Acad Sci U S A. 89(2):504-8 (1992).
Ecke, et al., “Possible identity of kallikrein binding protein with protein C inhibitor,”Agents Actions Suppl. 38 (Pt 1):182-9 (1992).
Edgell, et al., “Permanent cell line expressing human factor VIII-related antigen established by hybridization,”Proc. Natl. Acad. Sci. (USA) 80:3734-3737 (1983).
Engelman, et al., “Identifying Nonpolar Transbilayer Helices in Amino Acid Sequences of Membrane Proteins,”Annu. Rev. Biophys. Chem. 15:321-53 (1986).
Esmon & Owen, “Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C,”Proc. Natl. Acad. Sci. (USA) 78(4):2249-2252 (1981).
Esmon & Schwartz, “An Update on Clinical and Basic Aspects of the Protein C Anticoagulant Pathway,”Trends Cardiovasc. Med. 5(4):141-148 (1995).
Esmon, “Factors regulating the inhibition of thrombin by antithrombin III,” inChemistry and Biology of Thrombin, R. L. Lundblad, J. W. Fenton, II, and K. G. Mann, editors. Ann Arbor Science, Ann Arbor., 403-411 (1977).
Esmon, “Protein S and Protein C—Biochemistry, Physiology, and Clinical Manifestation of Deficiencies,”Trends Cardiovasc. Med. 2(6):214-220 (1992).
Esmon, “The Roles of Protein C and Thrombomodulin in the Regulation of Blood Coagulation,”J. Biol. Chem. 264(9):4743-4746 (1989).
Esmon, et al., “Complex Formation Between Thrombin Thrombomodulin Inhibits Both Thrombin-catalyzed Fibrin Formation and Factor V Activation,”J. Biol. Chem. 257(14):7944-7947 (1982).
Esmon, et al., “Protein C Activation,”Methods Enzymol. 222:359-385 (1993).
Fukudome & Esmon, “Identification, Cloning, and Regulation of a Novel Endothelial Cell Protein C/Activated Protein C Receptor*,”J. Biol. Chem. 269(42):26486-26491 (1994).
Fukudome, et al., “Identification, Cloning, and Regulation of a Novel Endothelial Cell Protein C/Activated Protein C Receptor,”Circulation90(4):I133 (1994).
Fukudome & Esmon, “M
Esmon Charles T.
Fukudome Kenji
Andres Janet L.
Emch Gregory S
Oklahoma Medical Research Foundation
LandOfFree
Cloning and regulation of an endothelial cell protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cloning and regulation of an endothelial cell protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cloning and regulation of an endothelial cell protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3645551